Indaptus Therapeutics Receives Notice of Allowance for Strategic Patent

Indaptus Therapeutics Receives Notice of Allowance for Strategic Patent

Indaptus Therapeutics Receives Notice of Allowance for Strategic Patent - Oops!Something went wrong.Please try again later. Key Patent for Platform Technology to Treat or Inhibit HBV and HIV Infections NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that the United States Patent and Trademark Office has issued a notice of allowance for claims related to the Company’s platform technology. The patent, titled, “Methods of Treatment of Infections Using Bacteria,” (Application No. 16/584,644) provides broad protection for the application of the Company’s platform technology alone and in combination with standards of care for the treatment and inhibition of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections. “We are delighted to expand our growing patent estate and this notice …
More on: finance.yahoo.com